During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
Global T-Cell Immunotherapy Market Growing Rapidly In Coming Years For Advanced Stage Cancer Treatment
on May 23, 2018 at 5:56 am
A new market study, titled “Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis”, has been featured on WiseGuyReports. Cancer is a class of disease which is classified by an uncontrolled cell growth. There are various types of cancer ... […]
PODCAST: Using the immune system to fight cancer (Ep. 29)
on May 22, 2018 at 5:23 am
Orlando Sentinel health reporter Naseem Miller talks with Dr. Mark Socinski, the executive medical director of the Florida Hospital Cancer Institute, about immunotherapy and what these groundbreaking drugs mean in the battle against cancer. Socinski has ... […]
Lowering cholesterol improves cancer-fighting immunotherapy
on May 19, 2018 at 12:03 am
A new study has found that when cholesterol levels are reduced, cancer immunotherapy becomes more effective. The findings offer a simple way to improve this fledgling technology. Immunotherapy is a fairly new but successful method of treating cancer. […]
Men May Gain More From Cancer Immunotherapy
on May 17, 2018 at 8:34 am
THURSDAY, May 17, 2018 (HealthDay News) -- Male cancer patients seem to fare significantly better following immunotherapy treatment than female patients, new research indicates. "Both sex and gender can potentially affect the strength of the body's immune ... […]
The Hutch closes in on a cancer cure
on May 17, 2018 at 7:04 am
A dozen trials are underway now at The Hutch and the affiliated Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance for a broad range of blood cancers, lung cancer, breast cancer and melanoma. A clinical trial for pancreatic cancer could ... […]
Cancer: Does sex affect the outcome of immunotherapy?
on May 17, 2018 at 12:12 am
Immunotherapy for advanced cancer is gaining popularity as a treatment strategy. But scientists are now asking an important question: do biological differences between men and women influence the therapy's effectiveness? Immunotherapy — a type of ... […]
Roche immunotherapy combination increases lung cancer survival - study
on May 16, 2018 at 7:26 pm
(Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage ... […]
Cancer Research Institute Celebrates Sixth Annual Cancer Immunotherapy Month™ in June
on May 16, 2018 at 11:06 am
30 days of education and awareness programming for patients, caregivers, and the public about cancer immunotherapy and clinical trials Join in #WearWhite Day on Friday, June 15, our signature social media awareness-raising campaign Scientific expert panel ... […]
Global Cancer Immunotherapy Market Growth Opportunities: Merck, Hoffman La Roche
on May 14, 2018 at 10:14 pm
May 15, 2018 (marketresearch.biz via COMTEX) -- The research study “Global Cancer Immunotherapy Industry” provides strategic appraisal of the Cancer Immunotherapy market. Our expedition specialists acutely determine the momentous aspects of the Global ... […]
Cancer Immunotherapy Market is Supposed to Reach US$ 145 Billion By 2024
on May 14, 2018 at 12:23 pm
May 14, 2018 (Heraldkeeper via COMTEX) -- New York, May 14, 2018: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report ... […]
via Google News and Bing News